What is D&D Pharmatech?
D&D Pharmatech is a clinical-stage global biotechnology firm established in 2014, with operations spanning Korea and the US. The company's unique model involves funding the development of novel medicines through specialized, disease-specific subsidiary companies. These subsidiaries are founded and strategically guided by leading medical research faculty, ensuring a strong foundation in scientific innovation and clinical expertise. This approach positions D&D Pharmatech at the forefront of therapeutic development, aiming to address unmet medical needs across various disease areas.
How much funding has D&D Pharmatech raised?
D&D Pharmatech has raised a total of $198.9M across 3 funding rounds:
Series B
$137.1M
Series C
$51M
Debt
$10.8M
Series B (2019): $137.1M with participation from LB Investment, Magna Investment, InterVest, Octave Life Sciences, and Smilegate Investment
Series C (2021): $51M led by KOREA INVESTMENT & SECURITIES, DS Asset Management, Kudos Venture Capital, and Praxis Capital Partners
Debt (2025): $10.8M, investors not publicly disclosed
Key Investors in D&D Pharmatech
LB Investment
LB Investment is a venture capital firm that invests in transformative technologies aimed at enhancing human life, partnering with entrepreneurs to foster groundbreaking innovations across sectors like deep-tech and healthcare.
Smilegate Investment
Smilegate Investment is a venture capital firm that operates within the software industry, focusing on early-stage investments and supporting innovative companies with the potential for significant market impact.
KOREA INVESTMENT & SECURITIES
KOREA INVESTMENT & SECURITIES is a leading financial services firm in Korea, specializing in securities brokerage, investment banking, and asset management, with a strong history in developing the Korean capital market.
What's next for D&D Pharmatech?
The recent major strategic investment into D&D Pharmatech signals a pivotal phase for the company, likely focused on accelerating clinical trials, expanding its research and development capabilities, and potentially preparing for commercialization. This infusion of capital will empower D&D Pharmatech to further its mission of bringing innovative medicines to market, leveraging its established network of top-tier medical research faculty and its subsidiary-based development model. The company's continued growth trajectory suggests a strategic focus on advancing its pipeline and solidifying its position within the competitive biotech landscape.
See full D&D Pharmatech company page
